SCHEMBL2618698

SCHEMBL2618698

CCC(C)c1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.49
MAPK1 P28482 1/20 0.49
ACHE P22303 1/20 0.48
MAPT P10636 4/20 0.46
CYP3A4 P08684 1/20 0.46
CA9 Q16790 1/20 0.46
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
TUBB4A P04350 3/20 0.44
TUBB P07437 3/20 0.44
TUBA3C P0DPH7 3/20 0.44
TUBA1B P68363 3/20 0.44
TUBA4A P68366 3/20 0.44
TUBB4B P68371 3/20 0.44
TUBB3 Q13509 3/20 0.44
TUBB2A Q13885 3/20 0.44
TUBB8 Q3ZCM7 3/20 0.44
TUBA3E Q6PEY2 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4098658 1.00 PTGS2 (0.54) PTGS2L3MBTL1MAPK1ACHEMAPT
SCHEMBL10110894 1.00 PTGS2 (0.54) PTGS2L3MBTL1MAPK1ACHEMAPT
SCHEMBL8403278 0.88 PTGS2 (0.42) PTGS2L3MBTL1MAPK1ACHEMAPT
SCHEMBL24498543 0.86 PTGS2 (0.48) PTGS2L3MBTL1MAPK1ACHEMAPT
SCHEMBL12133486 0.84 PDE4A (0.42) PTGS2L3MBTL1MAPK1MAPTCYP3A4
SCHEMBL11233982 0.83 PTGS2 (0.45) PTGS2L3MBTL1MAPK1ACHEMAPT
SCHEMBL20373607 0.83 ALDH1A1 (0.43) MAPTALDH1A1LMNATP53ALOX12
SCHEMBL13375683 0.81 ALDH1A1 (0.41) PTGS2L3MBTL1MAPK1ACHEMAPT
SCHEMBL6721159 0.81 ALDH1A1 (0.45) ACHEMAPTCYP3A4CA9ALDH1A1
SCHEMBL14399655 0.80 CYP3A4 (0.48) PTGS2ACHECYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-20230189802-A1 MONOTERPENOID/PHENYLPROPANOID-CONTAINING COMPOUNDS AND METHODS OF THEIR MAKING AND USE AS BAITS KITTRICH CORPORATION 2023-06-22 US disclosed
US-20220388968-A1 INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF PURDUE RESEARCH FOUNDATION 2022-12-08 US disclosed
US-20170298056-A1 SMALL MOLECULE INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2017-10-19 US disclosed
US-20160022642-A1 Compounds Useful for Promoting Protein Degradation and Methods Using Same YALE UNIVERSITY 2016-01-28 US disclosed
US-20150119435-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY 2015-04-30 US disclosed
WO-2013170147-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY (US) 2013-11-14 WO disclosed
US-8426432-B2 Inhibitors of dihydrofolate reductase with antibacterial antiprotozoal, antifungal and anticancer properties UNIVERSITY OF CONNECTICUT (US) 2013-04-23 US disclosed
US-8206886-B2 Photosensitive composition and pattern-forming method using the photosensitive composition FUJIFILM CORPORATION (JP) 2012-06-26 US disclosed
US-8158326-B2 Photosensitive composition, compound for use in the photosensitive composition, and method of pattern formation with the photosensitive composition FUJIFILM CORPORATION (JP) 2012-04-17 US disclosed
US-7521168-B2 Compound that has a reduction potential higher than that of diphenyl iodonium salt and generates an acid upon irradiation of an actinic ray or radiation. FUJIFILM CORPORATION (JP) 2009-04-21 US disclosed
US-7510822-B2 Stimulation sensitive composition and compound FUJIFILM CORPORATION (JP) 2009-03-31 US disclosed
US-20090075202-A1 PHOTOSENSITIVE COMPOSITION, COMPOUND FOR USE IN THE PHOTOSENSITIVE COMPOSITION, AND METHOD OF PATTERN FORMATION WITH THE PHOTOSENSITIVE COMPOSITION FUJIFILM CORPORATION (JP) 2009-03-19 US disclosed
US-7449573-B2 Photosensitive composition, compound for use in the photosensitive composition, and method of pattern formation with the photosensitive composition FUJIFILM CORPORATION (JP) 2008-11-11 US disclosed
US-20080274421-A1 PHOTOSENSITIVE COMPOSITION AND PATTERN FORMING METHOD USING THE SAME FUJIFILM CORPORATION (JP) 2008-11-06 US disclosed
US-7432034-B2 Negative resist composition FUJIFILM CORPORATION (JP) 2008-10-07 US disclosed
US-20080241745-A1 Mixture of alkali soluble polymer, crosslinking agent, acid generator ; radiation with actinic radiation; quaternary ammonium compound FUJIFILM CORPORATION (JP) 2008-10-02 US disclosed
US-7341817-B2 Photosensitive composition, compound for use in the photosensitive composition, and pattern forming method using the photosensitive composition FUJIFILM CORPORATION (JP) 2008-03-11 US disclosed
US-7323286-B2 Photosensitive composition, compound used in the same, and patterning method using the same FUJIFILM CORPORATION (JP) 2008-01-29 US disclosed
US-7189492-B2 Photosensitive composition and pattern forming method using the same FUJI PHOTO FILM CO., LTD. (JP) 2007-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298056-A1 SMALL MOLECULE INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF CD4, CCR5, CCR1 PTGS2 2422/4885L3MBTL1 395/4885MAPK1 1216/4885
US-20150119435-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME PSMG3, ERAP1, SMURF2 PTGS2 3411/4885L3MBTL1 691/4885MAPK1 4383/4885
US-20230189802-A1 MONOTERPENOID/PHENYLPROPANOID-CONTAINING COMPOUNDS AND METHODS OF THEIR MAKING AND USE AS BAITS CYP51A1, CYP4A22, ACHE PTGS2 313/4885L3MBTL1 709/4885MAPK1 2806/4885
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 PTGS2 624/4885L3MBTL1 2331/4885MAPK1 1593/4885
US-20160022642-A1 Compounds Useful for Promoting Protein Degradation and Methods Using Same AR, SHBG, PSMG3 PTGS2 3176/4885L3MBTL1 1936/4885MAPK1 4223/4885
US-20220388968-A1 INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF SPTBN1, CTTN, HBG1 PTGS2 4419/4885L3MBTL1 3115/4885MAPK1 614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.